Mar 30, 2023 8:30am EDT RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
Mar 08, 2023 8:30am EST RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem™ as a Treatment Option for Locally Advanced Pancreatic Cancer
Mar 02, 2023 8:30am EST RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
Jan 25, 2023 8:30am EST RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
Jan 18, 2023 8:30am EST RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
Jan 05, 2023 8:30am EST RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
Dec 15, 2022 8:30am EST RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
Nov 17, 2022 8:30am EST RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
